Volker Seibert, Lörrach (DE); Olivier Léger, Saint-Sixt (FR); Marc Van Dijk, Bosch en Duin (NL); Taha Merghoub, Jersey City, NJ (US); David Schaer, Mamaroneck, NY (US); Gerd Ritter, New York, NY (US); and Takemasa Tsuji, Buffalo, NY (US)
Assigned to AGENUS INC., Lexington, MA (US); Memorial Sloan-Kettering Cancer Center, New York, NY (US); and Ludwig Institute for Cancer Research Ltd., Zurich (CH)
Filed by Agenus Inc., Lexington, MA (US); Memorial Sloan-Kettering Cancer Center, New York, NY (US); and Ludwig Institute for Cancer Research Ltd., Zurich (CH)
Filed on Aug. 21, 2020, as Appl. No. 16/999,374.
Application 16/999,374 is a continuation of application No. 16/355,268, filed on Mar. 15, 2019, granted, now 10,829,559.
Application 16/355,268 is a continuation of application No. 16/175,453, filed on Oct. 30, 2018, granted, now 10,280,226, issued on May 7, 2019.
Application 16/175,453 is a continuation of application No. 14/724,452, filed on May 28, 2015, granted, now 10,155,818, issued on Dec. 18, 2018.
Claims priority of provisional application 62/161,250, filed on May 13, 2015.
Claims priority of provisional application 62/004,071, filed on May 28, 2014.
Prior Publication US 2021/0070872 A1, Mar. 11, 2021
1. An isolated antibody that specifically binds to human GITR, comprising a VH comprising the VH CDR1, VH CDR2, and VH CDR3 amino acid sequences and a VL comprising the VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of SEQ ID NOs: 249 and 435; 251 and 437; 254 and 440; 255 and 441; 259 and 444; 276 and 458; 277 and 459; 280 and 453; 284 and 463; 304 and 519; 276 and 440; 276 and 444; 276 and 453; 345 and 440; 345 and 444; 345 and 453; 249 and 440; 215 and 400; 217 and 401; 218 and 402; 219 and 403; 220 and 404; 221 and 405; 222 and 406; 223 and 407; 224 and 408; 225 and 409; 226 and 410; 227 and 411; 228 and 413; 229 and 414; 230 and 415; 231 and 416; 232 and 418; 233 and 419; 234 and 420; 236 and 421; 237 and 423; 239 and 425; 240 and 426; 241 and 427; 242 and 428; 243 and 429; 244 and 430; 245 and 431; 246 and 432; 247 and 433; 248 and 434; 250 and 436; 252 and 438; 253 and 439; 256 and 442; 258 and 443; 261 and 445; 262 and 446; 263 and 447; 264 and 448; 267 and 451; 268 and 452; 270 and 454; 271 and 455; 272 and 456; 273 and 457; 280 and 460; 281 and 461; 283 and 462; 285 and 464; 287 and 467; 288 and 468; 290 and 469; 291 and 470; 294 and 471; 296 and 472; 297 and 473; 298 and 474; 299 and 475; 301 and 476; 304 and 477; 305 and 481; 306 and 482; 308 and 483; 313 and 484; 314 and 485; 315 and 486; 316 and 488; 319 and 489; 320 and 490; 322 and 491; 323 and 492; 324 and 493; 325 and 494; 327 and 495; 328 and 496; 333 and 497; 336 and 498; 338 and 499; 339 and 500; 340 and 501; 342 and 502; 343 and 503; 350 and 504; 354 and 505; 355 and 506; 356 and 507; 358 and 508; 359 and 509; 360 and 510; 362 and 511; 363 and 512; 364 and 513; 365 and 515; 366 and 516; 367 and 517; 368 and 518, respectively.